94 related articles for article (PubMed ID: 34783936)
1. Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced computed tomography.
Maehira H; Tsuji Y; Iida H; Mori H; Nitta N; Maekawa T; Kaida S; Miyake T; Tani M
Int J Clin Oncol; 2022 Feb; 27(2):373-382. PubMed ID: 34783936
[TBL] [Abstract][Full Text] [Related]
2. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
[TBL] [Abstract][Full Text] [Related]
3. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
4. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
8. Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Goto S; Yoshizawa T; Ishido K; Seino H; Morohashi S; Ogasawara H; Kubota S; Ogasawara K; Nakamura A; Hakamada K; Kijima H
Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36799183
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
Wang ZJ; Zhang TT; An C; Ko AH; Tempero M; Collisson E; Yeh BM
AJR Am J Roentgenol; 2020 Sep; 215(3):610-616. PubMed ID: 32755156
[No Abstract] [Full Text] [Related]
10. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
11. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis.
Guo C; Zhuge X; Wang Q; Xiao W; Wang Z; Wang Z; Feng Z; Chen X
Cancer Imaging; 2018 Oct; 18(1):37. PubMed ID: 30333055
[TBL] [Abstract][Full Text] [Related]
12. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
[TBL] [Abstract][Full Text] [Related]
13. CT Density in the Pancreas is a Promising Imaging Predictor for Pancreatic Ductal Adenocarcinoma.
Fukuda Y; Yamada D; Eguchi H; Hata T; Iwagami Y; Noda T; Asaoka T; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2762-2769. PubMed ID: 28634666
[TBL] [Abstract][Full Text] [Related]
14. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nakajo M; Maemura K; Arima S; Yoshiura T
Pancreas; 2019; 48(10):1360-1366. PubMed ID: 31688602
[TBL] [Abstract][Full Text] [Related]
15. Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation.
Yamashita R; Perrin T; Chakraborty J; Chou JF; Horvat N; Koszalka MA; Midya A; Gonen M; Allen P; Jarnagin WR; Simpson AL; Do RKG
Eur Radiol; 2020 Jan; 30(1):195-205. PubMed ID: 31392481
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
17. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
18. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.
Takahashi M; Nojima H; Kuboki S; Horikoshi T; Yokota T; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
Pancreatology; 2020 Sep; 20(6):1205-1212. PubMed ID: 32819845
[TBL] [Abstract][Full Text] [Related]
19. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
20. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.
Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
